789 Immune checkpoint blockade augments cyclophosphamide induced anti-tumor immunity by expanding effector CD8+ T cell clones in a preclinical melanoma model

789 Immune checkpoint blockade augments cyclophosphamide induced anti-tumor immunity by expanding effector CD8+ T cell clones in a preclinical melanoma model

Bibliographic Details
Main Authors:	Alan N Houghton, Jedd D Wolchok, Taha Merghoub, Daniel Hirschhorn, Linda Hamadene, Yacine Marouf, Allison B Warner, Mariam M George, Nicholas J Ceglia
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness
by: Daniel Hirschhorn, et al.
Published: (2021-10-01)

1444 Pharmacologic LDH inhibition redirects intratumoral glucose consumption and improves response to CTLA-4 blockade
by: Jedd D Wolchok, et al.
Published: (2023-11-01)

Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.
by: Francesca Avogadri, et al.
Published: (2010-09-01)

CTLA-4 and PD-1 pathway Blockade : Combinations in the Clinic
by: Margaret Kathleen Callahan, et al.
Published: (2015-01-01)

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
by: Ning Yang, et al.
Published: (2022-10-01)

ATMRIJ TESTING789
by: TESTING789
Published: (2020)

33 Dynamic monitoring of response to immune checkpoint blockade through deep-learning empowered ultra-sensitive liquid biopsy in melanoma
by: Jedd Wolchok, et al.
Published: (2020-11-01)

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
by: Adam D Cohen, et al.
Published: (2010-05-01)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
by: Xia Liu, et al.
Published: (2022-10-01)

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
by: Dmitriy Zamarin, et al.
Published: (2017-02-01)

Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations
by: Nicola Principe, et al.
Published: (2022-05-01)

Tympanoplasty Outcomes: A Review of 789 Cases
by: Shabbir Indorewala, et al.
Published: (2015-03-01)

Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma
by: Sadna Budhu, et al.
Published: (2021-01-01)

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
by: Janet Retseck, et al.
Published: (2018-07-01)

619 Pharmacologic modulation of tumor glycolysis to improve responses to immune checkpoint blockade therapy
by: Taha Merghoub, et al.
Published: (2021-11-01)

Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade
by: Arnab Ghosh, et al.
Published: (2022-09-01)

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
by: Hyejin Choi, et al.
Published: (2019-04-01)

Meta-analysis of preclinical measures of efficacy in immune checkpoint blockade therapies and comparison to clinical efficacy estimates
by: Juan Miguel Tenorio-Pedraza, et al.
Published: (2023-08-01)

Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer
by: Souhil Lebdai, et al.
Published: (2019-06-01)

Immune effector mechanisms in malaria.
by: Marsh, K, et al.
Published: (2006)

Autophagy in immunity and infection : a novel immune effector /
by: Deretic, Vojo
Published: (2006)

7.89 Topics in Computational and Systems Biology, Fall 2007
by: Burge, Christopher
Published: (2007)

21W.789 Communicating with Mobile Technology, Spring 2011
by: Barrett, Edward C., et al.
Published: (2023)

Decreto número 789 de abril 16 de 1990
by: Salud Ministerio de
Published: (1990-02-01)

525 Investigating dynamic IDO-Kyn-AhR pathway-induced tumor immunosuppression using imaging modality to optimize AhR therapeutic intervention
by: Jedd D Wolchok, et al.
Published: (2023-11-01)

MCT4 blockade increases the efficacy of immune checkpoint blockade
by: Christian Schmidl, et al.
Published: (2023-10-01)

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
by: Said Dermime, et al.
Published: (2021-10-01)

Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity
by: Wei Xie, et al.
Published: (2019-11-01)

Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma
by: Kimberly Loo, et al.
Published: (2022-01-01)

Immune Checkpoint Blockade sensitivity and Progression-Free Survival associates with baseline CD8+ T cell clone size and cytotoxicity
by: Watson, R, et al.
Published: (2021)

Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8+ T cell clone size and cytotoxicity
by: Watson, RA, et al.
Published: (2021)

Immune-Checkpoint Blockade Therapy in Lymphoma
by: Ayumi Kuzume, et al.
Published: (2020-07-01)

The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance
by: Eugenia Opolka-Hoffmann, et al.
Published: (2021-01-01)

L13A F789 (17-24) [fotograf udara]
by: Malaysia. Direktorat Pemetaan Negara

The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial’s Impact
by: Arter ZL, et al.
Published: (2024-01-01)

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines
by: Srinivasan Roopa, et al.
Published: (2004-04-01)

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
by: Dmitriy Zamarin, et al.
Published: (2014-01-01)

556 Establishment of a novel preclinical model for evaluating immune checkpoint blockade-induced antitumor immunological memory in lung cancer
by: Ichiro Kinoshita, et al.
Published: (2023-11-01)

A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment
by: A. Farias, et al.
Published: (2021-07-01)

Eradication of Established Murine Skin Tumors by Cyclic Chemoimmunotherapy with Cyclophosphamide and Effector T Cells
by: Koh Nakata, et al.
Published: (2011-01-01)